2006
Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial. Journal Of Endovascular Therapy 2006, 13: 701-710. PMID: 17154704, DOI: 10.1583/05-1704.1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlloysAngioplasty, BalloonAnti-Bacterial AgentsAtherosclerosisBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleDouble-Blind MethodDrug CarriersFemaleFemoral ArteryHumansKaplan-Meier EstimateMaleMiddle AgedProspective StudiesProsthesis FailureRecurrenceSafetySirolimusStentsTreatment OutcomeConceptsChronic limb ischemiaAnkle-brachial indexBare stent groupRestenosis rateSirolimus groupLimb ischemiaStent groupSuperficial femoral artery occlusionType C lesionsDouble-blinded studySymptoms of claudicationBare nitinol stentsMajority of patientsSuperficial femoral arteryFemoral artery occlusionStent restenosis rateNitinol self-expanding stentsSelf-expanding stentsTypes of stentsTVR ratesTLR rateArtery occlusionC lesionsClinical outcomesDrug-Eluting
2003
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. Circulation 2003, 108: 1316-1323. PMID: 12939213, DOI: 10.1161/01.cir.0000087601.45803.86.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyEndpoint DeterminationFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexStentsTreatment OutcomeConceptsComposite end pointTarget vessel revascularizationIschemia-driven target vessel revascularizationPrimary percutaneous coronary interventionAbciximab treatmentPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionCoronary interventionEnd pointPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsInfarct artery reocclusionPrespecified secondary analysisEvent-free survivalFactorial design trialLack of effectAbciximab useAngiographic substudyCADILLAC trialTVR ratesPrimary angioplastyPrimary stentingAngiographic outcomes